Endocrine Abstracts

Prostate cancer (PC) is currently the most commonly diagnosed non-cutaneous cancer affecting UK men. Androgen deprivation therapy (ADT) has traditionally been used as the gold standard treatment for advanced PC. Despite the initial response to androgen ablation, tumours relapse and become refractory to clinically approved anti-androgens, resulting in castration-resistant PC (CRPC). In CRPC, androgen receptor (AR) signalling is inappropriately restored by AR splice variants (AR...